WO2003045408A1 - Composition pharmaceutique contre la grippe issue de la pharmacopee traditionnelle de la medecine chinoise et mode d'elaboration - Google Patents

Composition pharmaceutique contre la grippe issue de la pharmacopee traditionnelle de la medecine chinoise et mode d'elaboration Download PDF

Info

Publication number
WO2003045408A1
WO2003045408A1 PCT/CN2001/001592 CN0101592W WO03045408A1 WO 2003045408 A1 WO2003045408 A1 WO 2003045408A1 CN 0101592 W CN0101592 W CN 0101592W WO 03045408 A1 WO03045408 A1 WO 03045408A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
hours
amount
traditional chinese
Prior art date
Application number
PCT/CN2001/001592
Other languages
English (en)
Chinese (zh)
Inventor
Wei Xiao
Original Assignee
Jiangsu Kanion Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Kanion Pharmaceutical Co., Ltd filed Critical Jiangsu Kanion Pharmaceutical Co., Ltd
Priority to AU2002221511A priority Critical patent/AU2002221511A1/en
Priority to PCT/CN2001/001592 priority patent/WO2003045408A1/fr
Publication of WO2003045408A1 publication Critical patent/WO2003045408A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating colds and a preparation method thereof.
  • a cold is a common exogenous disease.
  • the milder is called a cold and the severer is called a severe cold or a flu. It is highly contagious and often causes widespread epidemics. The occurrence of this disease is caused by six sensations of exogenous feelings and seasonal viruses.
  • Wind is the main cause, but in different seasons, it is often combined with other current times and hurt people. Cold and wind-heat are more common.
  • the evil of summer dampness can also cause sickness.
  • the wind is light and windy, it often causes coke, the lungs are in the chest, the main breath, the airway is the way to go up and down, and the throat is the system. It is opened outside the nose, outside the fur, and outside the guard, so the external evil comes from the mouth, nose, and fur.
  • the lung guards bear the brunt, and soon after the feeling of evil, the symptoms of the health watch and the upper focal lung system appeared.
  • the symptoms of clinical manifestations include wind cold, wind heat and heat and dampness.
  • Fengreganmao, fever, headache, cough, dry mouth, and sore throat which are equivalent to influenza, upper respiratory tract infection, acute flat body inflammation, and mumps in modern medicine. It is a common clinical condition with a high incidence, and can be affected by men, women, and children all year round.
  • traditional Chinese medicine preparations for treating the above diseases have a long disintegration time and a slow onset of action.
  • the object of the present invention is to provide a traditional Chinese medicine composition with fast absorption, good curative effect, no side effects, and convenient taking, and a preparation method thereof; another object of the present invention is to provide a new pharmaceutical use of the above composition.
  • Distilled aqueous solution is collected separately; medicine residue and burdock, light bamboo leaves, licorice Add callus 6 to 10 times water, cook for 1-3 times, each time for 1-3 hours, combine decoction and filter; combine the above solutions, concentrate to 80 ° C and the relative density is not lower than 1.15, centrifuge The supernatant was concentrated to 80 and the relative density was 1.30.
  • honeysuckle thick paste vacuum dried, pulverized the dry paste into fine powder, added volatile oil and refined edible vegetable oil, milled by colloid, sieved, and pressed into soft gum. ⁇ ; The content of each soft capsule ⁇ weighs 0.45g, When the crude drugs in 2.24g.
  • the oral dosage of the capsules of the present invention is 2 capsules once, 3 times a day. Compared with the prior art, the capsule of the invention has fast onset, good curative effect, small oral dose, and convenient taking.
  • the disintegration time of the capsules of the present invention is 8-13 minutes, the content of chlorogenic acid in the finished product is 0.15-0.19%, and the prescribed amount of volatile oil content includes 0.95-1.20 (ml) of essential oil of nepeta, and 2-2.20 (ml) of volatile oil of mint. , Forsythia volatile oil 3.90-4.20 (ml).
  • the stability indicates that the volatile oil of the invention has good preservation during the observation period, and the tests are all positive; the content of chlorogenic acid is high and stable.
  • the capsule of the present invention The contents of capsule (including refined soybean oil) are provided by Lianyungang Kangyuan Pharmaceutical Co., Ltd., batch number: 961005. 2. Excipients: Contains refined soybean oil, provided by Lianyungang Kangyuan Pharmaceutical Co., Ltd. 3. Influenza virus (type A-I): Microbiology research of basic medical school of Nanjing University of Traditional Chinese Medicine. 4. E.coli 0111B4 endotoxin: product of Shanghai Institute of Biological Products, Ministry of Health, batch number: 940301. 5. Aspirin: produced by Nanjing Pharmaceutical Factory, batch number: 930613. 6. Croton oil: Provided by the Chinese Medicine Preparation Room of our school. 7.
  • influenza virus embryo culture was measured MLD: According to literature methods, embryo after infection with influenza virus, was taken into chick Nang 10-2 dilution, ⁇ 10 ⁇ 10-4, 10-5, 10- 6 times, take 5 ⁇ 1 of them for nasal infection in mice (6 mice in each group), and one week later, the infection is statistically small. The mortality of the mice was calculated and the minimum lethal dose (MLD) of the influenza virus infected mice was calculated. Table 1. Minimum lethal dose (MLD) of influenza virus infected mice
  • Injecting a clinically equivalent amount of the capsules of the present invention can not significantly reduce the mortality of mice infected with influenza virus: but when the dosage of the capsules of the present invention is doubled and tripled, that is, 3.44, 6.88g crude drug / kg can significantly reduce the infection Mortality of influenza virus mice (P ⁇ 0.05, P ⁇ 0.01).
  • mice Twenty rabbits whose body temperature ranged from 38.6 to 39.5 ° C and whose body temperature fluctuated within 0.3 ⁇ were randomly divided into 4 groups according to the basal body temperature stratification, namely: the vehicle group, the aspirin group (0. lg / kg), one group of capsules of the present invention (0.6g crude drug / kg, equivalent to a clinically equivalent amount), two groups of capsules of the present invention (1.8g raw / kg, equivalent to three times the clinically equivalent amount).
  • Each of the above administration groups was administered orally by intragastric administration, and the volume of administration was equal: the excipient group was intragastrically administered with an equal volume of excipients. Gavage was continued for three consecutive days.
  • each rabbit was injected with E. coli endotoxin 150 g / kg from the vein of the ear. After 0.5, 1, 2, 3, 4, and 6 hours after endotoxin challenge, each rabbit was measured.
  • Body temperature based on the average body temperature measured three times before the medicine as the base, calculate the rabbit body temperature change value ( ⁇ T) at each measurement point time, take the temperature change value ( ⁇ T) as the ordinate, and time as the abscissa, and make the body temperature over time Change the curve, and use the trapezoidal division method to obtain the area AUC under the curve;
  • TCM diagnostic criteria chills, fever, nasal congestion, runny nose, sneezing, cough, headache, general malaise and other symptoms; pale tongue or red edge, thin white or yellow moss, floating pulse; abnormal weather or careless living Caused by sudden onset, all around the clock, more common in winter and spring.
  • TCM criteria rheumatic fever: main symptoms: fever, bad wind, nasal congestion and / or yellowish cloudy snot, sore throat or dryness; secondary symptoms: headache, cough, sputum yellow or white, Sweating, thirsty, red tongue, thin yellow or white fur, floating pulses. There are more than 3 main symptoms and more than 2 secondary diseases, which can be identified as rheumatic fever.
  • the day is 1 course of treatment, observe 1 course of treatment.
  • the same kind of Chinese and Western medicine preparations shall not be used.
  • Treatment group 100 6.17 ⁇ 1.61 6.01 ⁇ 1.33 324> 0.05 33.56 46 29. 993 ⁇ 4.86 -3.573 ⁇ 4.32 4.29 ⁇ 0.001 t value 0.184 0.770 0.375 0.149 0.146 0.280
  • Nine flavor medicines take honeysuckle and add 10 times the amount of 90% ethanol to reflux for 3 times, 2 hours each Combined extracts, filtered, recovered ethanol, concentrated to a thick paste, and the relative density at 80 ° C is not less than 1. 30. Save separately; after boiling 4 times the amount of fresh tempeh, boil it at 80t! The extracts were combined for 1 hour each time, filtered, and stored separately; volatile oils were extracted from mint, nepeta, and forsythia.
  • Formulated amounts of forsythia, mint, and nepeta were taken, and 10 times the amount of water in the medicinal material was used as a solvent. After soaking for 6 hours, Extract the volatile oil for 9 hours by distillation. Collect the distilled aqueous solution in another device. Add 10 times more water to the dregs, burdock, light bamboo leaves, licorice, and eustoma, and cook 3 times for 3 hours each time. Combine the decoction and filter. Combine the above. Concentrated to 80 ° C, the relative density is not less than 1. 15, centrifugation, the supernatant is concentrated to 80 ° C, the relative density is 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne, d'une part une composition pharmaceutique issue de la pharmacopée de la médecine traditionnelle chinoise, et d'autre part son mode d'élaboration. Cette composition se prépare à partir de Lonicera japonica, Forsythia suspensa, Herba menthae, Herba schizeneptae, Semen sojae praeparatum, Fructus arctii, Radix platycodi, Herba lophatheri et Radix glycyrrhizae. Le médicament obtenu selon le mode d'élaboration de l'invention, quand il est utilisé contre la grippe, s'absorbe rapidement, se prend facilement, ne présente pas d'effets secondaires, et présente un effet thérapeutique bénéfique.
PCT/CN2001/001592 2001-11-29 2001-11-29 Composition pharmaceutique contre la grippe issue de la pharmacopee traditionnelle de la medecine chinoise et mode d'elaboration WO2003045408A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002221511A AU2002221511A1 (en) 2001-11-29 2001-11-29 An influenza treating pharmaceutical composition of traditional chinese medicine and method for preparation thereof
PCT/CN2001/001592 WO2003045408A1 (fr) 2001-11-29 2001-11-29 Composition pharmaceutique contre la grippe issue de la pharmacopee traditionnelle de la medecine chinoise et mode d'elaboration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/001592 WO2003045408A1 (fr) 2001-11-29 2001-11-29 Composition pharmaceutique contre la grippe issue de la pharmacopee traditionnelle de la medecine chinoise et mode d'elaboration

Publications (1)

Publication Number Publication Date
WO2003045408A1 true WO2003045408A1 (fr) 2003-06-05

Family

ID=4574898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/001592 WO2003045408A1 (fr) 2001-11-29 2001-11-29 Composition pharmaceutique contre la grippe issue de la pharmacopee traditionnelle de la medecine chinoise et mode d'elaboration

Country Status (2)

Country Link
AU (1) AU2002221511A1 (fr)
WO (1) WO2003045408A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497482A4 (fr) * 2009-11-05 2013-05-01 Korea Inst Oriental Medicine Fig. 2:composition destinée à prévenir et à traiter des maladies induites par le virus de la grippe
CN105249473A (zh) * 2015-11-26 2016-01-20 安徽燕之坊食品合肥有限公司 一种治愈小儿流感的杂粮冲剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1083370A (zh) * 1993-01-02 1994-03-09 重庆中药二厂 银翘解毒口服液的剂型及工艺流程
CN1243717A (zh) * 1998-07-30 2000-02-09 王建平 治疗感冒咳嗽的药物及其制备方法
CN1057451C (zh) * 1994-08-16 2000-10-18 欧致新 一种小儿感冒药及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1083370A (zh) * 1993-01-02 1994-03-09 重庆中药二厂 银翘解毒口服液的剂型及工艺流程
CN1057451C (zh) * 1994-08-16 2000-10-18 欧致新 一种小儿感冒药及其制备方法
CN1243717A (zh) * 1998-07-30 2000-02-09 王建平 治疗感冒咳嗽的药物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
F.J. DUAN ET AL.: "Science of TCM Fomula", vol. 6, 1995, SHANG HAI SCIENCE AND TECHNOLOGY PRESS, pages: 28 - 29 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497482A4 (fr) * 2009-11-05 2013-05-01 Korea Inst Oriental Medicine Fig. 2:composition destinée à prévenir et à traiter des maladies induites par le virus de la grippe
US8591962B2 (en) 2009-11-05 2013-11-26 Korea Institute Of Oriental Medicine Composition for preventing and treating influenza-virus-induced diseases
CN105249473A (zh) * 2015-11-26 2016-01-20 安徽燕之坊食品合肥有限公司 一种治愈小儿流感的杂粮冲剂及其制备方法

Also Published As

Publication number Publication date
AU2002221511A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
JP5336656B2 (ja) 気管支炎を治療するための麻黄含有医薬組成物およびその調製方法
CN105012392A (zh) 一种用于治疗鼻炎的中药组合物及其制备方法
CN111317798A (zh) 解毒化湿利咽中药组合物及其应用
CN110237174A (zh) 一种治疗感冒咳嗽的燥湿中药组合物及其制备方法
CN102139051A (zh) 清热解毒软胶囊在制备用于治疗病毒性肺炎药物中的应用
CN102526236B (zh) 一种治疗流行性感冒的药物及其制备方法
CN104436145A (zh) 一种预防和/或治疗过敏性鼻炎及过敏性哮喘的药物组合物
CN101757408A (zh) 一种治疗红斑狼疮的药物及其制备方法
CN104324280B (zh) 一种治疗鼻咽癌的中药组合物及其制备方法
WO2003045408A1 (fr) Composition pharmaceutique contre la grippe issue de la pharmacopee traditionnelle de la medecine chinoise et mode d'elaboration
CN106075229A (zh) 一种治疗风热感冒的中药组合物制剂
WO2016041462A1 (fr) Composition pharmaceutique pour le traitement de la ronchopathie, son procédé de préparation et utilisation associée
CN105998475A (zh) 一种治疗儿童过敏性鼻炎的中药组合物及其制备方法
CN110742923A (zh) 一种治疗产妇拘乳的中药组合物、中药制剂及其制备方法
CN104274750A (zh) 一种用于治疗急性支气管炎、上呼吸道感染的中药组合物
CN103705599B (zh) 一种治疗咳嗽的药物组合物及其制备方法
CN103705857B (zh) 用于预防放射性口腔粘膜反应的中药组合物
CN117018132B (zh) 一种用于治疗咳嗽变异性哮喘的中药
CN107744583A (zh) 缓解上气道炎症、控制上气道过敏反应的中药组合物、其制备方法及其应用
CN106389589A (zh) 一种具有止咳化痰功效的药物
CN107441317A (zh) 一种用于特禀体质过敏性鼻炎治疗的中药方剂
CN105561007A (zh) 一种用于治疗小儿流行性感冒的中药制剂及制备方法
CN104435133A (zh) 一种退烧药
CN105031379A (zh) 一种用于治疗上呼吸道感染的中药制剂及制备方法
CN105079640A (zh) 止咳平喘汤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP